Trademark: 88938201
Word
NABOTA
Status
Registered
Status Code
700
Status Date
Tuesday, June 15, 2021
Serial Number
88938201
Registration Number
6383994
Registration Date
Tuesday, June 15, 2021
Mark Type
4000
Filing Date
Thursday, May 28, 2020
Published for Opposition
Tuesday, March 30, 2021

Trademark Owner History
DAEWOONG PHARMACEUTICAL CO., LTD. - Original Registrant

Classifications
5 Botulinum toxin for medical use for use in the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction and pelvic pain; Pharmaceutical preparations, namely, acne medications, acne treatment preparations, adrenal hormone preparations, alcohol for topical use, allergy and allergy relief medications, analgesics, androgen preparations, anesthetics for surgical and non-surgical use, antacids, bactericides, antiarrhythmics, antibiotics, anticoagulants, anticonvulsants, antidepressants, antidiabetic preparations, antivirals, anti-cancer preparations, anti-infectives, anti-inflammatories, antipyretics, antibacterial pharmaceuticals, calcium channel blockers, beta blockers, chemical compounds for drug delivery, eye drops, eye patches for medical purposes, hair growth stimulants, vaccines, vaccine adjuvants, vaccine stabilizers, diuretics, amino acids for medical purposes; Medicines for the treatment of gastrointestinal diseases; chemical preparations for pharmaceutical purposes for the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, and pelvic pain; chemico-pharmaceutical preparations for the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, and pelvic pain. drugs for medical purposes for the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, and pelvic pain; Medicines for human purposes for the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, and pelvic pain; pharmaceutical preparations for activating cellular function; Adjuvants for medical purposes; pharmaceutical preparations for central nerve treatment, namely, for the treatment of sequelae caused by damage to the central nerve in the brain; dermatological pharmaceutical products, namely, injectable botulinum toxin for refining wrinkles; pharmaceutical preparations for treating skin disorders; antibiotic preparations; pharmaceutical preparations for chemical disorder treatment, namely, for treatment of chemical imbalance in the brain

Trademark Events
Jun 15, 2021
Registered-Principal Register
Mar 30, 2021
Official Gazette Publication Confirmation E-Mailed
Mar 30, 2021
Published For Opposition
Mar 10, 2021
Notification Of Notice Of Publication E-Mailed
Feb 22, 2021
Approved For Pub - Principal Register
Feb 1, 2021
Teas/Email Correspondence Entered
Feb 1, 2021
Correspondence Received In Law Office
Jan 27, 2021
Assigned To Lie
Oct 15, 2020
Teas Response To Office Action Received
Aug 28, 2020
Notification Of Non-Final Action E-Mailed
Aug 28, 2020
Non-Final Action E-Mailed
Aug 28, 2020
Non-Final Action Written
Aug 28, 2020
Assigned To Examiner
Jun 17, 2020
New Application Office Supplied Data Entered In Tram
Jun 1, 2020
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24